66. IgA腎症 IgA nephropathy Clinical trials / Disease details


臨床試験数 : 255 薬物数 : 261 - (DrugBank : 79) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 137

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02433236
(ClinicalTrials.gov)
September 201529/4/2015Open Label Study of Fostamatinib in the Treatment of IgA NephropathyA Phase 2, Multi-Centre, Open Label Extension Study of Fostamatinib in the Treatment of IgA Nephropathy for Patients Who Participated in Study C-935788-050IGA NephropathyDrug: Fostamatinib Disodium tablet 100 mg;Drug: Fostamatinib Disodium tablet 150 mgRigel PharmaceuticalsNULLWithdrawn18 Years72 YearsBoth0Phase 2NULL
2NCT02112838
(ClinicalTrials.gov)
October 201410/4/2014Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) NephropathyA Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA NephropathyIGA NephropathyDrug: Fostamatinib 150 mg;Drug: Fostamatinib 100 mg;Drug: PlaceboRigel PharmaceuticalsNULLCompleted18 Years70 YearsAll76Phase 2United States;Austria;Germany;Hong Kong;Taiwan;United Kingdom;Singapore;Switzerland
3EUCTR2014-000331-16-AT
(EUCTR)
25/08/201422/07/2014N/AA Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy - N/A IgA nephropathy (IgAN);Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]Product Name: Fostamatinib 100 mg tablet
Product Code: R935788
INN or Proposed INN: Fostamatinib
Other descriptive name: FOSTAMATINIB DISODIUM
Product Name: Fostamatinib 150 mg tablet
Product Code: R935788
INN or Proposed INN: Fostamatinib
Other descriptive name: FOSTAMATINIB DISODIUM
Rigel Pharmaceuticals IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
75Phase 2United States;Hong Kong;Taiwan;Singapore;Austria;United Kingdom;Switzerland
4EUCTR2014-000331-16-GB
(EUCTR)
28/07/201408/05/2014N/AA Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy - N/A IgA nephropathy (IgAN);Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]Product Name: Fostamatinib 100 mg tablet
Product Code: R935788
INN or Proposed INN: Fostamatinib
Other descriptive name: FOSTAMATINIB DISODIUM
Product Name: Fostamatinib 150 mg tablet
Product Code: R935788
INN or Proposed INN: Fostamatinib
Other descriptive name: FOSTAMATINIB DISODIUM
Rigel Pharmaceuticals IncNULLNot Recruiting Female: yes
Male: yes
92 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited States;Hong Kong;Taiwan;Singapore;Austria;Switzerland;United Kingdom